2EyesVision aims to reduce uncertainty in multifocal corrections

2EyesVision is a Spanish startup specializing in the creation, development, and commercialization of ophthalmic technologies. The company focuses on developing devices for the ophthalmic industry with a special emphasis on correcting cataracts and presbyopia (age-related farsightedness), an ocular condition that affects 100 percent of the population above the age of forty-five.

The company’s core technology, SimVis Gekko, is an ophthalmic instrument that enables patients to experience multifocal corrections before they commit to surgery or to contact lens fitting. While multifocal correction, often in the form of contact lenses or intraocular lenses, gives patients corrected vision at different distances without the need for glasses, it is a new visual experience and not all patients can readily adapt to it. With SimVis, patients can try different corrections and choose which works best for them.

2EyesVision is one of ten finalist companies with optics, imaging, and photonics-enabled technologies that is working with NextCorps’ Luminate NY accelerator as part of its fourth cohort. Each company received an initial investment of $100,000 and is participating in the six-month program, which helps the selected companies speed the commercialization of their technologies and businesses. This September at Finals 2021 (date to be announced) they will compete for up to $2 million in follow-on investment. Funding for the $25 million program is provided through the Finger Lakes Forward Upstate Revitalization Initiative.

“Technology innovation is leading to tremendous advancements that are allowing health care providers to offer life-changing benefits to their patients,” said Dr. Sujatha Ramanujan, managing director of Luminate. “Companies like 2EyesVision are leading the way by empowering patients to take a more proactive role in their treatment decisions, and Luminate is committed to helping them accelerate the availability of SimVis.”

The Rochester Business Journal is featuring profiles of the companies that are helping to write the next chapter in Rochester’s history as the world’s center for optics, photonics, and imaging (OPI).

We caught up with Carlos Dorronsoro, 2EyesVision’s CEO, to discuss why the company’s technology will change the ophthalmic industry.

What problem does your technology solve?

Today only 8 percent of cataract surgeries around the world involve multifocal corrections and these procedures are performed by less than 20 percent of ophthalmologists. Empowering clinicians with tools to reduce the uncertainty around patient satisfaction is key to encouraging more ophthalmologists to provide these highly-effective multifocal corrections. With SimVis, clinicians can reduce patient dissatisfaction (by screening out unsuitable patients), save time (patients can try the corrections in less than 10 minutes), and increase the market’s general adoption of multifocal lenses, which contributes to eye clinic profitability.